Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Secord on Treating Patients with Platinum Sensitive Ovarian Cancer

October 1st 2021

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Single-Agent and Combo Immunotherapy Garners Mixed Excitement in Gynecologic Cancers

September 30th 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

Investigators Seek to Preserve Fertility in Ovarian Malignant Germ Cell Tumors

September 28th 2021

Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.

Dr. Backes on Challenges Regarding Staging of Ovarian Germ Cell Tumors

September 28th 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

Progress Moves Full Steam Ahead in Gynecologic Malignancies

September 27th 2021

Jubilee Brown, MD, contextualizes updates in endometrial cancer and cervical cancer, frontline and second-line maintenance, and novel immune-oncology combination strategies in ovarian cancer.

Dr. O’Malley on Balstilimab and Zalifrelimab in Recurrent/Metastatic Cervical Cancer

September 24th 2021

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

Immunotherapy Combos, Novel Agents Hold Promise in Recurrent Ovarian Cancer

September 24th 2021

Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.

Dr. Salani on the Potential Impact of Ongoing Research in Ovarian Cancer

September 22nd 2021

Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.

Olaparib Rechallenge Improves PFS in Relapsed Ovarian Cancer Previously Treated With PARP Inhibition

September 17th 2021

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

Gynecologic Oncology Pioneer Franco Muggia Dies at 85

September 10th 2021

Franco Muggia, MD, a fixture at NYU Langone’s Perlmutter Cancer Center and a leader in the study and treatment of patients with gynecologic cancers, died on September 8, 2021. He was 85 years old.

Neo–Epitope-Based Vaccine Plus Pembrolizumab Under Exploration in Ovarian Cancer

September 1st 2021

The neo–epitope-based vaccine Tedopi is under investigation either alone or in combination with pembrolizumab as maintenance treatment vs best supportive care in patients with recurrent ovarian cancer following platinum-based chemotherapy as part of the phase 2 TEDOVA trial.

Dr. Wenham on the Potential for Immunotherapy in Ovarian Cancer

August 31st 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

Investigative Directions in Ovarian Cancer Continue to Comprise Multidisciplinary Approaches

August 27th 2021

Sanaz Memarzadeh, MD, PhD, focuses on these ongoing multidisciplinary research directions aimed at improving outcomes for patients with ovarian cancer.

Dr. Grisham on the Combination of VS-6766 With Defactinib in Ovarian Cancer

August 24th 2021

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Dr. Willmott on Expanding Genomic Testing in Ovarian Cancer

August 19th 2021

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer

August 19th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Dr. Grisham on the Rationale for Binimetinib in Low-Grade Serous Ovarian Cancer

August 19th 2021

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Dr. O’Malley on the Utility of Chemoimmunotherapy in Ovarian Cancer

August 16th 2021

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian Cancer

August 12th 2021

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Niraparib Maintains Safety, Efficacy in BRCA+ Ovarian Cancer, Irrespective of Setting

August 12th 2021

Maintenance niraparib has been shown to result in a significant progression-free survival benefit in patients with BRCA-mutated ovarian cancer following response to platinum-based chemotherapy.